KRAS and neoplasm: Part of the explanation of this problem might be traced back to different distribution of various KRAS mutations across various tumor types: in mCRC for example, KRAS G12D, G12V, and G12A are frequently observed, whereas G12C mutation accounts only for 9–10% of all KRAS mutations.